

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Myriam GOLEMBO et al.	Confirmation No.: 3940
Application No.: 10/664,605	Patent No.: 7,276,481 B2
Filing Date: September 15, 2003	Patent Date: October 2, 2007
For: METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS	Attorney Docket No.: 81408-4300

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050. The corrections requested are as follows:

Title Page:

Before Item (30), please insert the following:

-- (60) Provisional application No. 60/276,939, filed Mar. 20, 2001. --

Support for this change appears on the signed Declaration filed on March 10, 2004 in response to the Notice to File Missing Parts.

Column 51:

Line 9 (claim 6, line 6), change "(IGF-1)" to -- (IGF-1) --. Support for this change appears in application claim 40.

Line 17 (claim 9, line 2), before "in vitro", change "hone" to -- bone --. Support for this change appears in application claim 67.

Line 36 (claim 15, line 3), after "protein fusion", delete the second occurrence of "protein". This change is requested merely to correct a typographical error.

Line 39 (claim 15, line 6), change "(IGF-1)" to -- (IGF-1) --. Support for this change appears in application claim 77.

Column 52:

Line 5 (claim 20, line 1), before "bone" insert -- a --. Support for this change appears in application claim 82.

Line 30 (claim 27, line 1), after "claim", change "20" to -- 26 --. Support for this change appears in application claim 93.

Line 37 (claim 28, line 6), change "(1GF-1)" to -- (IGF-1) --. Support for this change appears in application claim 94.

The requested changes are to correct errors of a clerical or typographical nature and do not involve changes that would constitute new matter or require reexamination.

A fee of \$100 is believed to be due for this request. Please charge the required fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

10/17/07  
Date

Allan A. Fanucci  
Allan A. Fanucci, Reg. No. 30,256

**WINSTON & STRAWN LLP**  
**Customer No. 28765**

212-294-3311

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,276,481 B2  
APPLICATION NO. : 10/664,605  
DATED: : October 2, 2007  
INVENTOR(S) : Golembo et al.

Page 1 of 1

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Before Item (30), please insert the following:

-- (60) Provisional application No. 60/276,939, filed Mar. 20, 2001. --

Column 51:

Line 9 (claim 6, line 6), change "(IGF-1)" to -- (IGF-1) --.

Line 17 (claim 9, line 2), before "in vitro", change "hone" to -- bone --.

Line 36 (claim 15, line 3), after "protein fusion", delete the second occurrence of "protein".

Line 39 (claim 15, line 6), change "(IGF-1)" to -- (IGF-1) --.

Column 52:

Line 5 (claim 20, line 1), before "bone" insert -- a --.

Line 30 (claim 27, line 1), after "claim", change "20" to -- 26 --.

Line 37 (claim 28, line 6), change "(IGF-1)" to -- (IGF-1) --.



US007276481B2

(12) **United States Patent**  
**Golembo et al.**

(10) **Patent No.:** **US 7,276,481 B2**  
(45) **Date of Patent:** **Oct. 2, 2007**

(54) **METHOD AND COMPOSITION FOR  
TREATMENT OF SKELETAL DYSPLASIAS**

(75) Inventors: **Myriam Golembo**, Moshav Netayim  
(IL); **Avner Yayon**, Moshav Sitria (IL)

(73) Assignee: **ProChon Biotech Ltd.**, Ness-Ziona  
(IL)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 311 days.

(21) Appl. No.: **10/664,605**

(22) Filed: **Sep. 15, 2003**

(65) **Prior Publication Data**

US 2004/0138134 A1 Jul. 15, 2004

**Related U.S. Application Data**

(63) Continuation of application No. PCT/IL02/00229,  
filed on Mar. 20, 2002.

(30) **Foreign Application Priority Data**

Mar. 20, 2001 (IL) ..... 00142118

(51) **Int. Cl.**  
**A61K 38/00** (2006.01)

(52) **U.S. Cl.** ..... **514/13; 514/2; 435/1.1**

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,683,195 A	7/1987	Mullis et al.	435/6
4,683,202 A	7/1987	Mullis	435/91.2
4,965,188 A	10/1990	Mullis et al.	435/6
5,336,759 A	8/1994	Matsuo et al.	530/326
5,338,759 A	8/1994	Shechter et al.	514/492
5,434,133 A	7/1995	Tanaka et al.	514/12
5,846,932 A	12/1998	Lowe et al.	514/9
5,973,134 A	10/1999	Matsuo et al.	536/23.53
6,020,168 A	2/2000	Matsuo et al.	435/69.4
6,034,231 A	3/2000	Tanaka et al.	536/23.51
6,329,375 B1	12/2001	Tang et al.	514/250
6,344,459 B1	2/2002	Bridges et al.	514/234.5
2001/0025026 A1	9/2001	Heartlein et al.	514/12

**FOREIGN PATENT DOCUMENTS**

EP 0 528686 A2 \* 2/1993  
WO WO 00/61631 10/2000

**OTHER PUBLICATIONS**

Druker and Lydon, J Clin Invest. 2000; 105: 3-7.\*  
Suzuki et al. FEBS Letters, 1991; 282: 321-325.\*  
Yabuta EP 0528686 A2, published Feb. 1993.\*  
Rivera et al. Science 2000; 287: 826-830.\*  
Mericq et al. J Clin Endocrinol Metab. 2000; 85: 569-73.\*  
Hendy et al. Kidney Int. 2006; 69: 218-223.\*  
Agrawal, S. et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice," *Proc. Natl. Acad. Sci. USA*, vol. 88, pp. 7595-7599 (1991).

Brandt, R.R. et al., "Neutral Endopeptidase Regulates C-Type Natriuretic Peptide Metabolism But Does Not Potentiate Its Bioactivity In Vivo," *Hypertension*, vol. 30, No. 2, pp. 184-190 (1997).

Chang, P.L., "Microcapsules as Bio-organs for Somatic Gene Therapy," *Annals New York Academy of Sciences*, vol. 831, pp. 460-473 (1997).

Chen, H.H. et al., "C-Type Natriuretic Peptide: The Endothelial Component of the Natriuretic Peptide Systems," *J. of Cardiovasc. Pharmacol.*, vol. 32, Suppl. 3, pp. S22-S28 (1998).

Chen, H.H. et al., "Natriuretic Peptides in the Pathophysiology of Congestive Heart Failure," *Curr. Cardiol. Rev.*, vol. 2, pp. 198-205 (2000).

Chusho, H. et al., "Dwarfism and early death in mice lacking C-type natriuretic peptide," *PNAS*, vol. 98, No. 7, pp. 4016-4021 (2001).

Fingl, E. et al., "Chapter 1—General Principles," in *The Pharmacological Basis of Therapeutics* 5th edition, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).

Harvey, C.B. et al., "Molecular Mechanisms of Thyroid Hormone Effects on Bone Growth and Function," *Molecular Genetics and Metabolism*, vol. 75, pp. 17-30 (2002).

Kelly, P.A. et al., "Growth Hormone Receptor Signalling and Actions in Bone Growth," *Hormone Research*, vol. 55 (suppl. 2), pp. 14-17 (2001).

Kridel, S.J. et al., "Substrate Hydrolysis by Matrix Metalloproteinase-9," *J. Biol. Chem.*, vol. 276, No. 23, pp. 20572-20578 (2001).

Matsukawa, N. et al., "The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system," *Proc. Natl. Acad. Sci. USA*, vol. 96, pp. 7403-7308 (1999).

McCarthy, T.L. et al., "Local IGF-I expression and bone formation," *Growth Hormone & IGF Research*, vol. 11, pp. 213-219 (2001).

Mericq, V. et al., "Regulation of Fetal Rat Bone Growth by C-Type Natriuretic Peptide and cGMP," *Pediatric Research*, vol. 47, No. 2, pp. 189-193 (2000).

Murthy, K.S. et al., "Identification of the G Protein-activating Domain of the Natriuretic Peptide Clearance Receptor (NPR-C)," *J. Biol. Chem.*, vol. 274, No. 25, pp. 17587-17592 (1999).

Ohbayashi, H. et al., "Neutral endopeptidase 3.4.24.11 Inhibition Potentiates the Inhibitory Effects of Type-C Natriuretic Peptide on Leukotriene D<sub>4</sub>-Induced Airway Changes," *Clin. Exp. Pharma. Physiol.*, vol. 25, pp. 986-991 (1998).

(Continued)

*Primary Examiner*—Elizabeth Kemmerer

*Assistant Examiner*—Christina Borgeest

(74) *Attorney, Agent, or Firm*—Winston & Strawn LLP

(57) **ABSTRACT**

The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.

**30 Claims, 5 Drawing Sheets**

(60) Provisional application No.  
60/276,939, filed Mar. 20, 2001

51

5. The pharmaceutical composition according to claim 1 further comprising an inhibitor of fibroblast growth factor receptor 3 tyrosine kinase.

6. The pharmaceutical composition according to claim 1 wherein the natriuretic peptide is fused to a carrier protein forming a natriuretic peptide-carrier protein fusion protein; wherein the carrier protein is selected from the group consisting of growth hormone (GH), insulin like growth factor-1 (IGF-1) and thyroid hormone (TH).

7. The pharmaceutical composition according to claim 6 wherein the carrier protein comprises growth hormone.

8. The pharmaceutical composition according to claim 6 wherein said at least one natriuretic peptide is conjugated to a carrier protein forming a natriuretic peptide-carrier protein conjugate.

9. A method for increasing the size of a bone growth plate in a bone comprising treating the bone in vitro with an effective amount of at least one natriuretic peptide in a pharmaceutical composition according to claim 1.

10. The method according to claim 9 further comprising inhibiting the natriuretic peptide clearance receptor.

11. The method according to claim 9 further comprising an inhibitor of the neutral endopeptidase 24.11.

12. The method according to claim 11 wherein the inhibitor of neutral endopeptidase 24.11 is thiorphan or candoxatril.

13. The method according to claim 12 wherein the step of administering an inhibitor of neutral endopeptidase is performed simultaneously with the step of administering an effective amount of at least one natriuretic peptide.

14. The method according to claim 9 further comprising an inhibitor of fibroblast growth factor receptor 3 tyrosine kinase.

15. The method according to claim 9 wherein said at least one natriuretic peptide is fused to a carrier protein forming a natriuretic peptide-carrier protein fusion protein wherein the carrier protein is selected from the group consisting of growth hormone (GH), insulin like growth factor-1 (IGF-1) and thyroid hormone (TH).

16. The method according to claim 15 wherein the carrier protein fusion protein comprises growth hormone.

17. The method according to claim 9 wherein said at least one natriuretic peptide is conjugated to a carrier protein forming a natriuretic peptide-carrier protein conjugate.

52

18. The method according to claim 9 wherein the bone is a limb bone.

19. The method according to claim 18 wherein the limb bone is an achondroplastic bone.

20. A method for elongation of bone, comprising treating the bone in vitro with an effective amount of at least one natriuretic peptide in a pharmaceutical composition according to claim 1.

21. The method according to claim 20 further comprising inhibiting the natriuretic peptide clearance receptor.

22. The method according to claim 20 further comprising an inhibitor of the neutral endopeptidase 24.11.

23. The method according to claim 22 wherein the inhibitor of neutral endopeptidase 24.11 is thiorphan or candoxatril.

24. The method according to claim 22 wherein the step of administering an inhibitor of neutral endopeptidase is performed simultaneously with the step of administering an effective amount of at least one natriuretic peptide.

25. The method according to claim 20 further comprising an inhibitor of fibroblast growth factor receptor 3 tyrosine kinase.

26. The method according to claim 20 wherein said at least one natriuretic peptide is a natriuretic peptide fused to a carrier protein forming a natriuretic peptide-carrier protein fusion protein.

27. The method according to claim 20 wherein the carrier protein comprises growth hormone.

28. The method according to claim 20 wherein said at least one natriuretic peptide is conjugated to a carrier protein forming a natriuretic peptide-carrier protein conjugate wherein the carrier protein is selected from the group consisting of growth hormone (GH), insulin like growth factor-1 (IGF-1) and thyroid hormone (TH).

29. The method according to claim 20 wherein the bone is a limb bone.

30. The method according to claim 20 wherein the limb bone is an achondroplastic bone.

\* \* \* \* \*